TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
High-grade metaplastic breast carcinoma
clinicopathological characteristics
histological subtypes
immunophenotype
theranostic markers
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
08
12
2022
received:
27
09
2022
accepted:
13
12
2022
pubmed:
18
12
2022
medline:
4
3
2023
entrez:
17
12
2022
Statut:
ppublish
Résumé
High-grade metaplastic breast carcinoma (HG-MBC) is a rare subtype of invasive breast carcinoma, mostly triple-negative. Metaplastic carcinomas are less responsive to neoadjuvant chemotherapy and are associated with a worse outcome than invasive carcinomas of no special type. Clinicopathological characteristics and immunophenotype were retrospectively assessed in a series of 65 patients diagnosed with HG-MBC between 2005 and 2017 at the Curie Institute (antibody panel: oestrogen receptor [ER], progesterone receptor [PR], androgen receptor [AR], human epidermal growth factor receptor 2 [HER2], programmed death ligand-1 [PD-L1], and trophoblast cell surface antigen 2 [TROP2]). The median age at diagnosis was 59.5 years. Six (9%) patients had metastatic disease at diagnosis. Among the nonmetastatic patients receiving neoadjuvant therapy, 26% (5/19) achieved pathological complete response. Most tumours were pT1/pT2 (77%) and 12% were pN+. Histological subtypes (mixed, squamous, mesenchymal, and spindle cell) were 40%, 35.5%, 15.5%, and 9%, respectively. Tumour-infiltrating lymphocytes were low or moderate except when squamous differentiation was present. Most tumours were triple-negative (92%). AR and TROP2 were positive in 34% and 85% of the cases, respectively. PD-L1 was positive in tumour cells in 18% (cutoff: 1% of positive tumour cells) of the cases and in tumour-infiltrating immune cells in 40% (cutoff: 1% of tumour area) of the cases. Notably, spindle cell and mesenchymal metaplastic breast carcinomas were mostly PDL1-negative. Lastly, 21 (32.3%) cases were HER2-low, all being HER2 1+, with no HER2 2+. Metaplastic breast carcinoma could benefit from tailored therapeutic strategies adapted to the phenotypic specificities of histological subtypes.
Substances chimiques
CD274 protein, human
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
Receptors, Androgen
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-671Informations de copyright
© 2022 The Authors. Histopathology published by John Wiley & Sons Ltd.
Références
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann. Surg. Oncol. 2006; 14; 166-173.
Dwyer JB, Clark BZ. Low-grade fibromatosis-like spindle cell carcinoma of the breast. Arch. Pathol. Lab. Med. 2015; 139; 6.
Bataillon G, Fuhrmann L, Girard E et al. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. Histopathology 2018; 73; 273-283.
Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG. The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J. Cancer 2018; 9; 296-303.
Xiao M, Yang Z, Tang X, Mu L, Cao X, Wang X. Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast. Oncol. Lett. 2017; 14; 1971-1978.
Zhang Y, Lv F, Yang Y et al. Clinicopathological Features and prognosis of metaplastic breast carcinoma: experience of a major Chinese cancer center. PLoS One 2015; 10; e0131409.
Ong CT, Campbell BM, Thomas SM et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a National Oncology Database. Ann. Surg. Oncol. 2018; 25; 2249-2260.
Takala S, Heikkilä P, Nevanlinna H, Blomqvist C, Mattson J. Metaplastic carcinoma of the breast: prognosis and response to systemic treatment in metastatic disease. Breast J. 2019; 25; 418-424.
El Zein D, Hughes M, Kumar S et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin. Breast Cancer 2017; 17; 382-391.
Leyrer CM, Berriochoa CA, Agrawal S et al. Predictive factors on outcomes in metaplastic breast cancer. Breast Cancer Res. Treat. 2017; 165; 499-504.
Cimino-Mathews A, Verma S, Figueroa-Magalhaes MC et al. A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. Am. J. Clin. Pathol. 2016; 145; 365-372.
Mills MN, Yang GQ, Oliver DE et al. Histologic heterogeneity of triple negative breast cancer: a National Cancer Centre Database analysis. Eur. J. Cancer 2018; 98; 48-58.
Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010-2014. Oncologist 2018; 223; 481-488.
Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008; 26; 1275-1281.
Harbeck N, Gluz O. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast 2017; 34; S99-S103.
Tzanninis IG, Kotteas EA, Ntanasis-Stathopoulos I, Kontogianni P, Fotopoulos G. Management and outcomes in metaplastic breast cancer. Clin. Breast Cancer 2016; 16; 437-443.
Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 2018; 379; 2108-2121.
Schmid P, Cortes J, Pusztai L et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 2020; 382; 810-821.
Cortes J, Cescon DW, Rugo HS et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396; 1817-1828.
Dill EA, Gru AA, Atkins KA et al. PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am. J. Surg. Pathol. 2017; 41; 334-342.
Joneja U, Vranic S, Swensen J et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J. Clin. Pathol. 2017; 70; 255-259.
Zhai J, Giannini G, Ewalt MD et al. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing. Hum. Pathol. 2019; 86; 85-92.
Afkhami M, Schmolze D, Yost SE et al. Mutation and immune profiling of metaplastic breast cancer: correlation with survival. PLoS One 2019; 14; e0224726.
Doğukan R, Uçak R, Doğukan FM, Tanık C, Çitgez B, Kabukcuoğlu F. Correlation between the expression of PD-L1 and clinicopathological parameters in triple negative breast cancer patients. Eur. J. Breast Health 2019; 15; 235-241.
Morgan E, Suresh A, Ganju A et al. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. World J. Surg. Oncol. 2020; 18; 11.
Vranic S, Stafford P, Palazzo J et al. Molecular profiling of the metaplastic spindle cell carcinoma of the breast reveals potentially targetable biomarkers. Clin. Breast Cancer 2020; 20; 326-331.e1.
Chao X, Liu L, Sun P et al. Immune parameters associated with survival in metaplastic breast cancer. Breast Cancer Res. 2020; 22; 92.
Kalaw E, Lim M, Kutasovic JR et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. Br. J. Cancer 2020; 123; 1665-1672.
Gucalp A, Tolaney S, Isakoff SJ et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin. Cancer Res. 2013; 19; 5505-5512.
Traina TA, Miller K, Yardley DA et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J. Clin. Oncol. 2018; 36; 884-890.
Bonnefoi H, Grellety T, Tredan O et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann. Oncol. 2016; 27; 812-818.
Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann. Oncol. 2010; 21; 488-492.
Kim HM, Kim DH, Jung WH, Koo JS. Molecular classification of metaplastic carcinoma using surrogate immunohistochemical staining. Pathobiology 2014; 81; 69-77.
Teoh PY, Tan GC, Mahsin H, Wong YP. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters. Malays. J. Pathol. 2019; 41; 125-132.
Voutilainen S, Heikkilä P, Sampo M, Nevanlinna H, Blomqvist C, Mattson J. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. Acta Oncol. Stockh. Swed. 2021; 60; 1233-1239.
Bardia A, Mayer IA, Vahdat LT et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med. 2019; 380; 741-751.
Bardia A, Hurvitz SA, Tolaney SM et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 2021; 384; 1529-1541.
Gerratana L, Basile D, Buono G et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat. Rev. 2018; 68; 102-110.
Wang C, Pan B, Zhu H et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 2016; 7; 46482-46491.
Ambrogi F, Fornili M, Boracchi P et al. Trop-2 is a determinant of breast cancer survival. PLoS One 2014; 9; e96993.
Zhao W, Kuai X, Zhou X et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol. Rep. 2018; 40(2); 759-766.
Lai HW, Tseng LM, Chang TW et al. The prognostic significance of metaplastic carcinoma of the breast (MCB) - a case controlled comparison study with infiltrating ductal carcinoma. Breast 2013; 22; 968-973.